StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) stock analysis

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

StockData Score

Prices as of Nov 13, 2026How the score works

Value0Growth4Performance5Health3Dividend0

Mixed12 of 30 checks passed

AstraZeneca passes 12 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
4/6
Past performance
5/6
Financial health
3/6
Dividend
0/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 15.8%, above the 10% that usually covers the cost of capital.

  • Earnings grew over 5 years

    Net income grew 26.2% a year on average over the last five fiscal years.

  • EPS growing 10%+ a year

    Diluted EPS grew 45.8% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 45.3% over the last twelve months, against a 5-year average of 26.2% a year.

What to watch

  • Return on equity under 15%

    Return on equity was 21.5% over the last twelve months and averaged 13.0% over five years; we look for 15% on both.

  • High debt

    Debt is 58.6% of shareholders' equity, above the 40% we consider low.

  • Revenue growing under 10% a year

    Revenue grew 9.8% a year over the last three fiscal years, short of the 10% we look for.

  • Short-term assets don't cover short-term debts

    Current assets are 0.89 times current liabilities.

Valuation0/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth4/6
  • Revenue growing under 10% a year

    Revenue grew 9.8% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing 10%+ a year

    Diluted EPS grew 45.8% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 45.3% over the last twelve months, against a 5-year average of 26.2% a year.

  • Growing faster than the industry

    Revenue grew 8.6% over the last twelve months; the Drugs median is 7.7%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 81.9% over the last twelve months, against 81.1% a year earlier.

Past performance5/6
  • Return on equity under 15%

    Return on equity was 21.5% over the last twelve months and averaged 13.0% over five years; we look for 15% on both.

  • Return on capital over 10%

    Return on invested capital was 15.8%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    AstraZeneca's return on equity of 21.5% is above the Drugs median of -57.0%.

  • Earnings grew over 5 years

    Net income grew 26.2% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 17.4% over the last twelve months, against a 5-year average of 10.2%.

  • Net margin above the industry

    AstraZeneca's net margin of 17.4% is above the Drugs median of -53.5%.

Financial health3/6
  • High debt

    Debt is 58.6% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 126% five years ago to 58.6%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 49.4% of total debt.

  • Interest well covered

    Operating income covers interest expense 8.1 times.

  • Short-term assets don't cover short-term debts

    Current assets are 0.89 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6
  • No dividend

    AstraZeneca has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

We don't publish a fair value for AstraZeneca. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2015 to 2025

Gross margin

81.9%+1.8 pts over 5 years

Operating margin

23.4%+4.0 pts over 5 years

Net margin

17.4%+5.4 pts over 5 years

See a number that looks wrong?